Hasil Pencarian - Brendan Curti

  • Menampilkan 1 - 18 hasil dari 18
Perbaiki Hasil
  1. 1
    30 Molecular features associated with long survival on tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial

    30 Molecular features associated with long survival on tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial oleh Brendan Curti, Koustubh Ranade, Laura Collins, Marlana Orloff, Emma Leach, Sarah Stanhope, Adel Benlahrech, Kevin Kim

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

    760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab oleh William Redmond, Brendan Curti, John Cha, Walter Urba, Yoshinobu Koguchi, Brian Piening, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Correction: The society for immunotherapy of cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

    Correction: The society for immunotherapy of cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation oleh Marka Crittenden, Brendan Curti, Walter J Urba, Roxanne Payne, Steven K Seung, Christopher B Fountain, ShuChing Chang, Jessica Fleser, Kimberly Phillips, Ian Malkasian, Lyn B Dobrunick

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy

    Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy oleh Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb, William J. Murphy

    Diterbitkan 2017-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy

    A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy oleh Emma Bigelow, Suchi Saria, Brian Piening, Brendan Curti, Alexa Dowdell, Roshanthi Weerasinghe, Carlo Bifulco, Walter Urba, Noam Finkelstein, Elana J Fertig, Alex Baras, Neeha Zaidi, Elizabeth Jaffee, Mark Yarchoan

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

    737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastati... oleh Brendan Curti, Igor Puzanov, Mateusz Opyrchal, Christopher J Nirschl, Mehmet A Bilen, Kristin Morris, Justin C Moser, Ildefonso Rodriguez Rivera, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K Subramanian, Sameer S Chopra, Randi Isaacs

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

    368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for tre... oleh Anh Nguyen, Adi Diab, Brendan Curti, Jonathan Zalevsky, Mary Tagliaferri, Christie Fanton, Evidio Domingo-Musibay, Wei Lin, Mehmet Bilen, Sandra D’Angelo, Andrew Brohl, Erkut Borazanci, Cat Haglund, Mona Vimal, Mann Muhsin, Mario Marcondes

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

    A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma oleh Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung, David H. Lawson

    Diterbitkan 2018-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies

    763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies oleh Ning Li, William L Redmond, Brendan Curti, Shuhang Wang, Herui Yao, Erwei Song, Henry Yu, Giorgio Massimini, Ming-Hong Hu, Rongliang Lou, Wanping Geng, Sanlong Wang, Meiling Zhang, Rongchu Chen, Baotian Qin, John Mao, Shaoshan Wang

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

    Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry oleh Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong, Janice P. Dutcher

    Diterbitkan 2017-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Regulation of human and mouse bystander T cell activation responses by PD-1

    Regulation of human and mouse bystander T cell activation responses by PD-1 oleh Catherine T. Le, Logan V. Vick, Craig Collins, Cordelia Dunai, Michael K. Sheng, Lam T. Khuat, Isabel Barao, Sean J. Judge, Ethan G. Aguilar, Brendan Curti, Maneesh Dave, Dan L. Longo, Bruce R. Blazar, Robert J. Canter, Arta M. Monjazeb, William J. Murphy

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

    420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study... oleh Mario Sznol, Adi Diab, Brendan Curti, Igor Puzanov, Gregory Daniels, Jonathan Zalevsky, Ute Hoch, Mary Tagliaferri, Michael Hurwitz, Scott Tykodi, Michele Maio, Sekwon Jang, Tuan Nguyen, Wei Lin, Karl Lewis, Alexander Spira, Ewa Kalinka, Daniel Cho, Shanhong Guan, Erika Puente, Sue Currie

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

    Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies oleh Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel, Patricia LoRusso, Amy Weise, Joseph Eder, Brendan Curti, Michael Oberst

    Diterbitkan 2019-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

    718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies oleh Li Zhang, Ning Li, Brendan Curti, Stephen Spurgeon, Elisabeth Heath, Naomi Hunder, Eric Jonasch, Dingwei Ye, Zhu Chen, Melissa Reimers, Stephen Park, Weidong Li, Paolo Caimi, Ulka N Vaishampayan, Benjamin Garmezy, Swetha Kambhampati, Catherine Diefenbach, Noah Kornblum, Weili Zhao, Sharon Ma, Eric Song, Justin A Call

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab

    Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab oleh Helen Gogas, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz Couselo, Adi Diab, Caio Pereira, Gaëlle Quéreux, Shahneen Sandhu, Brendan Curti, Nikhil I. Khushalani, Matthew H. Taylor, Gregory A. Daniels, Anna Spreafico, Tarek Meniawy, Alfons J. M. Van Den Eertwegh, Yongliang Sun, Yull Arriaga, Ming Zhou, Georgina V. Long, Céleste Lebbé

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

    High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma oleh Ann W. Silk, Ann W. Silk, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Brendan Curti, Janice M. Mehnert, Kim Margolin, David McDermott, Joseph Clark, Jenna Newman, Praveen K. Bommareddy, Praveen K. Bommareddy, Lisa Denzin, Lisa Denzin, Lisa Denzin, Saltanat Najmi, Saltanat Najmi, Azra Haider, Azra Haider, Weichung Shih, Michael P. Kane, Andrew Zloza, Andrew Zloza

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

    A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma oleh Ann W. Silk, Ann W. Silk, Ann W. Silk, Ann W. Silk, Brendan Curti, Jennifer Bryan, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P. Kane, Phoebe Hannon, Christopher Fountain, Jessica Felcher, Andrew Zloza, Andrew Zloza, Andrew Zloza, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Janice M. Mehnert, Janice M. Mehnert, Janice M. Mehnert, David F. McDermott, David F. McDermott

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

    Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence oleh Omid Hamid, Brendan Curti, Craig L Slingluff, Mohammed Milhem, Jose Lutzky, Suthee Rapisuwon, Brian Gastman, Takami Sato, Marcus O Butler, Robert Andtbacka, Eddy Hsueh, Robert Weber, John Glaspy, Sekwon Jang, Sajeve Thomas, Karl D Lewis, Leonel Hernandez-Aya, John Hyngstrom, Adam Berger, Edward Levine, Montaser F Shaheen, Vinay Gupta, Svetomir N Markovic, Tawnya Bowles, Joel Claveau, Prejesh Philips, Shernan G Holtan, William Schmidt, Juan Paramo, Arvinda Padmanabhan, Daniel Milton, Andrew Pecora, Suprith Badarinath, John Keech, Sujith Kalmadi, Pallavi Kumar, Anna Bar, J Thaddeus Beck, Jeffrey B Travers, Catalin Mihalcioiu, Peter Beitsch, Edward C McCarron, Deepti Behl, Brent Blumenstein, Joanna J Peterkin

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: